Christine Brown
Institution Name:
City of Hope, Beckman Research Institute
Total Awards:
1
Award Value:
$12,753,854
Awards as PI
Program Type | Institution | Grant Title | Award Value |
---|---|---|---|
Clinical Trial Stage Projects | City of Hope, Beckman Research Institute | Phase I Study of Chimeric Antigen Receptor Engineered Central Memory T cells for the Treatment of Malignant Glioma | $12,753,854 |
Total: $12,753,854.00 |
Awards as Co-PI
Early Translational III | Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells |
Publications
- JAMA Oncol 2020 Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid. (PubMed: 33030521)
- Cancer Discov 2021 IFNgamma Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity. (PubMed: 33837065)
- Cancer Immunol Res 2021 Mitochondria as Playmakers of CAR T-cell Fate and Longevity. (PubMed: 34344697)
- J Immunother Cancer 2021 Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. (PubMed: 34083417)
- Cancer Discov 2021 CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. (PubMed: 33328215)
- Neuro Oncol 2022 Off-the-shelf, steroid-resistant, IL13Ralpha2-specific CAR T cells for treatment of glioblastoma. (PubMed: 35100373)
- Neoplasia 2022 Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma. (PubMed: 35550513)
- PLoS Comput Biol 2022 Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy. (PubMed: 35081104)
- Neurooncol Adv 2021 Repeatability of tumor perfusion kinetics from dynamic contrast-enhanced MRI in glioblastoma. (PubMed: 34988454)
- Front Immunol 2021 Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy? (PubMed: 34899716)